Liver transplantation for autoimmune hepatitis in Peru: Outcomes and recurrence

Martín Padilla, Rosario Mayorga, Félix Carrasco, Tayana Bedregal, Fernando Bobadilla, Carlos Rondón, José Chaman

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Background. Liver transplantation is the only therapy for end-stage liver disease. Cirrhosis secondary to autoimmune hepatitis (AIH) is an indication in 4-6% of adult transplants. Aims. To describe the outcomes and recurrence of AIH in liver transplant patients. Material and methods. Twenty patients were retrospectively studied. Results. The female/male ratio was 3:1, the median age was 36.7 years (range, 16 to 39 years), and the median MELD score was 18.5. According to serological analysis, 19 patients were AIH type 1 and one patient was AIH type 2. AIH was associated with human leukocyte antigen (HLA) DR13+ and DR4+. The overall 5-year patient and graft survival rates were 94 and 85%, respectively. Three (15.7%) cases of recurrent AIH were diagnosed based on histological evidence. Clinical and histological features of acute and chronic rejection were present in four (20%) and three (16.6%) patients, respectively. Conclusion. AIH frequently affected young women, was the most frequent indication for liver transplantation. Rejection and recurrence were commonly associated with AIH, but did not affect patient survival. No significant relationship between HLA-DR type and recurrence was found. Rapid progression to cirrhosis should be considered in severe recurrences.
Original languageAmerican English
Pages (from-to)222-227
Number of pages6
JournalAnnals of Hepatology
StatePublished - 1 Mar 2012
Externally publishedYes

Fingerprint Dive into the research topics of 'Liver transplantation for autoimmune hepatitis in Peru: Outcomes and recurrence'. Together they form a unique fingerprint.

  • Cite this

    Padilla, M., Mayorga, R., Carrasco, F., Bedregal, T., Bobadilla, F., Rondón, C., & Chaman, J. (2012). Liver transplantation for autoimmune hepatitis in Peru: Outcomes and recurrence. Annals of Hepatology, 222-227.